This week, the top managed care news included the Congressional Budget Office's new score for the American Health Care Act; the White House released its fiscal year 2018 budget; and a cancer drug approval that is a first for the FDA.
Based on the results of the phase 2 ZUMA-1 trial in patients with refractory non-Hodgkin lymphoma, Kite Pharma has submitted for, and received, a priority review for its chimeric antigen receptor (CAR)-T cell treatment, axicabtagene ciloleucel.
Leonard Lichtenfeld, MD, provides insight on the ethical and patient access considerations with off-label communications.
The drug is now indicated for adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors that lack suitable alternative treatments or that have progressed on treatment.
A study published in the Annals of Internal Medicine reports that black Medicare enrollees are less likely to receive colonoscopy from more highly-rated physicians, which could increase their risk for interval colorectal cancer.


May 15-19, 2015
New Orleans, LA
May 29-June 2, 2015
Chicago, IL
June 11-14, 2015
Vienna, Austria
June 17-20, 2015
Lugano, Switzerland
COPD Compendium
Diabetes Compendium
GI Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium